# First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

> **NCT06799065** · PHASE1 · RECRUITING · sponsor: **Accent Therapeutics** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Breast Cancer Recurrent
- Ovarian Cancer
- High-grade Serous Ovarian Carcinoma
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** ATX-295

## Key facts

- **NCT ID:** NCT06799065
- **Lead sponsor:** Accent Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799065, "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06799065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*